Trials / Unknown
UnknownNCT02822534
The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients
the Pharmacokinetics,Pharmacodynamics,Safety and Tolerability Study Following Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
SP2086 is a novel inhibitor of Dipeptide base peptidase 4, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this single-dose and multiple-dose study the investigators evaluated the safety, tolerability and PK/PD profiles of SP2086 in Type 2 Diabetes Patients .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SP2086 | the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively. |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2016-07-01
- First posted
- 2016-07-04
- Last updated
- 2016-07-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02822534. Inclusion in this directory is not an endorsement.